Collegium Pharmaceutical vs Mirum Pharmaceuticals
COLL and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COLL and MIRM compare
Mirum Pharmaceuticals is the larger company, worth 7.6 times as much as Collegium Pharmaceutical ($6.1B against $808M).
Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 7.7% for Collegium Pharmaceutical).
Collegium Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with −139% at Mirum Pharmaceuticals.
Collegium Pharmaceutical scores higher on the StockData Score (10 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COLL | MIRM |
|---|---|---|
| Size and price | ||
| Market cap | $808M | $6.1B |
| Share price | $24.81 | $94.61 |
| Change, 1 year | −43.0% | 35.7% |
| Change, 5 years | 31.6% | 503% |
| Beta (5Y) | 0.47 | 0.64 |
| Employees | 423 | 372 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 24.8× | – |
| P/S | 1.0× (better) | 9.9× |
| P/B | 2.7× | – |
| EV/EBITDA | 5.3× | – |
| P/FCF | 2.4× | – |
| FCF yield | 41.6% (better) | −3.7% |
| Fair value | $44.75 | – |
| Margin of safety | 44.6% | – |
| Growth | ||
| Revenue growth (TTM) | 7.7% | 44.0% (better) |
| Revenue growth, 5Y average | 20.3% | – |
| Net income growth (TTM) | −34.7% | – |
| EPS growth (TTM) | −37.9% | – |
| EPS growth, 5Y average | 17.9% | – |
| Profitability | ||
| Gross margin | 59.0% | – |
| Operating margin | 15.2% (better) | −135% |
| Net margin | 4.7% (better) | −139% |
| FCF margin | 41.3% (better) | −37.0% |
| Return on equity | 13.4% (better) | −703% |
| Return on invested capital | 160% | – |
| Financial health | ||
| Interest coverage | 1.6× (better) | −62.1× |
| Current ratio | 1.01 | 2.86 (better) |
| Altman Z-score | 0.81 (better) | −0.12 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 121% | 110% |
| Held by insiders | 4.3% | 9.2% |
| Insider net buying, 12 months | −$4.4M (better) | −$31.5M |
| Short interest, % of float | 16.7% | 11.1% |
Go deeper
- COLL stock overview
- COLL income statement
- COLL valuation and score
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.